Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Provider Spotlight |


 

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.

 

Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button

 

Tech Q&A with Likarda, LLC

February 5, 2018 | Posted by Team in Provider Spotlight |


Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.


GS: Nice to meet you, Lisa! Why do clients come to Likarda?

LSB: Likarda is the company you come to when your scientific questions require complex solutions. Our scientists work to create and validate novel assays on a number of different projects, in a timely and efficient manner.

GS: What capabilities does Likarda have that differentiate the company from other service providers and cell-based assay experts?

LSB: We have a strong portfolio of platform technologies that allow us to conduct assays that just aren’t available at other companies. First of all, we have a series of patents around generating, in a high throughput manner, 3D spheroids for drug screening, efficacy testing, toxicity testing, etc. Our Likarda CC Microplate is made using standard plate formats, but in each well of a 384-well plate are 150 different single microwells, in each of which we can grow a different spheroid. That way, we can reduce the number of replicates, saving time and money for the client.

GS: There are many different plate-based models on the market — organoplates, microfluidic chips, etc. — How do Likarda’s plates compare?

LSB: The difference is that Likarda’s plates are really made for a high throughput format and are ideal for complex experiments, for example, when you need to work with multi-cell-type 3D cultures, in an as natural environment as possible. Most of the time, we don’t use any sort of gel or matrix for the 3D cultures — the plates are low-adherence, so the cells stick to each other and not to the plate. This makes the plates easy to work with. We do have a patented hydrogel technology which allows us to make microencapsulated cells using biocompatible materials. We are the first to use these materials for microencapsulation. Microplates and hydrogel — these two technologies really set us apart.

GS: Very cool. How would you describe Likarda’s team?

LSB: All of our scientists have advanced Masters’ degrees in biology or physiology or PhD’s in physiology or bioengineering. We’re a relatively small team, so everyone is involved and gives input into these complex studies that we typically do.

GS: Your clients seem very diverse!

LSB: Yes! Our clients are in the pharmaceutical and nutraceutical industries, as well as food supplements and hygiene. We do work for multinational companies as well as smaller startups.

GS: How has Likarda grown over the years? What lies in the future?

LSB: We started Likarda 5 years ago with money from family and friends. Within 17 months, we were revenue-positive! We’re revenue-driven, and we’re working also on our own products — microplates, hydrogel, regenerative medicine therapies we’re getting ready to take to market.

GS: Can you talk about Likarda’s certifications?

LSB: We’re a woman-owned company, we have the capability to run GLP studies, and we can maintain GMP status for drug development projects, we have continual environmental monitoring.

GS: So, I take it, Likarda has had a successful experience being part of the Science Exchange network.

LSB: Definitely — Science Exchange has been wonderful to work with! With Science Exchange, you have a sourcing agent assigned to you from the very start. That person really does a good job of figuring out what the client needs, and matching them to the right CRO for their research.

Connect with the Likarda team to discuss your project today by visiting www.scienceexchange.com/labs/likarda-llc.

Easing the Bioinformatics Bottleneck: OnRamp Bioinformatics

October 4, 2017 | Posted by Team in Provider Spotlight |

By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.comOnRamp Bio Logo

According to Tim Wesselman, CEO of today’s featured provider OnRamp Bioinformatics, there are only 15,000 bioinformaticians worldwide today to support more than 2 million biologists and other researchers. As a result, analysis has become the rate-limiting step in next-generation sequencing studies, and very large datasets may go un-analyzed to the point of obsoletion.

To ease this bottleneck, OnRamp Bio offers services that empower researchers with insights that they can understand and put into action.

Software as a service: accessible bioinformatics for non-experts

OnRamp Bio has made significant progress in making bioinformatics accessible to larger numbers of researchers. Earlier this year, OnRamp Bio launched a new software-as-a-service for RNA-Seq analysis, to meet the needs of researchers needing assistance in making decisions based on the large data sets yielded by RNA-Seq experiments.

Genomics big data and complex software analyses have historically required highly trained PhDs in Bioinformatics using complicated command-line tools. OnRamp Bio’s intuitive user interface, automated analyses and robust data management make it faster and easier for scientists, biologists, clinicians and other medical professionals to obtain interpretations of genomic data without the complexity of traditional deployments.

“IT complexity has stood in the way of progress for far too long. We’ve combined our deep knowledge of IT and biology to provide intuitive, integrated systems and services that accelerate mainstream adoption of NGS analyses within biotech and pharma,” said Tim Wesselman, CEO of OnRamp Bio. “For institutions focused on drug discovery, cancer research, diagnostic, or therapeutic development, OnRamp Bio can help show how to implement next generation sequencing to securely build into future research, while getting immediate answers more cost-efficiently.”

In addition to offering end-to-end genomic analysis services, OnRamp Bio recently made the news when it launched Rosalind™, the first-ever software platform specifically designed to simplify genomic analysis (named for one of the researchers who discovered the double helix structure of DNA).

Faces of OnRamp Bioinformatics

Jeremy Davis-Turak OnRamp BioJeremy Davis-Turak, VP of Bioinformatics, earned his Ph.D. in Bioinformatics and Systems Biology in the lab of Dr. Alexander Hoffmann at UCSD, researching kinetic models of co-transcriptional splicing.  In his studies, Dr. Davis-Turak developed analyses for RNA-seq, nascent RNA-seq, GRO-seq and MNase-seq that were intimately linked with mechanistic models.  He set up the Bioinformatics Core at the San Diego Center for Systems Biology, optimizing pipeline for RNA-seq and ChIP-seq.  

 

Jean Lozach OnRamp BioJean Lozach, Chief Technology Officer, joined OnRamp Bio after more than 25 years experience in Genomics, Bioinformatics and Information Technology at Illumina and UCSD. Jean brought deep experience and knowledge of biology, wet lab operations, microarrays, and next generation sequencing together with advanced bioinformatics, software development and enterprise IT infrastructure. Jean is recognized as an industry expert in genomics and bioinformatics, and has led tens of successful customer deployments of next generation sequencing and informatics systems.

Roshni Patel OnRamp BioRoshni Patel, Bioinformatician, has helped complete many projects for OnRamp Bio’s clients. She earned her BS of Bioinformatics from the University of California at San Diego, and she is passionate about breaking down workflow complexity, improving data metrics and visualization.

 

 

What Science Exchange Requesters are saying about OnRamp Bioinformatics

OnRamp Bio’s storefront shows several testimonials from Science Exchange requesters. One review, in particular, applauds both the breadth and quality of their services: “I highly recommend OnRamp for their Bioinformatics expertise. I have worked with them on several genomics and metagenomics projects and the team is professional, completes the work on deadline and budget, and generated results we hadn’t expected. OnRamp will work with you every step of the way, from project inception, through interfacing with sequencing partners, through developing novel informatics solutions for your project. OnRamp’s bioinformatics platform has many unique attributes that make it appealing, but their data and analysis tracking is just amazing: provenance for all your analyses from the minute the sequences arrive.”

 

Visit the OnRamp Bio storefront today to request some quotes!

 

The Robotic Cloud Laboratory for the Life Sciences: Transcriptic

September 20, 2017 | Posted by Team in Provider Spotlight |

Transcriptic LogoBy Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

 

In this Provider Innovation Profile, we’re proud to feature Transcriptic, whose automated cellular and molecular biology platform enables scalable life science research with flexibility and precision.

Automation is a rapidly advancing area of biotechnology, and Science Exchange hopes to give our researchers access to unique robotics platforms while helping them save on equipment costs and manage laboratory space limitations.

Transcriptic’s robotic cloud lab paradigm means biologists can be running experiments on the other side of the planet from their lab, leveraging a bank of robotic workcells for massive experimentation.

Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible.

Differentiators: Transparency, flexibility, multiplex-ity

Transcriptic Robotic Workcell

Multiple integrated automated devices per workcell

  • Transparency: No other service provider on the planet can tell you exactly how they run an experiment on the user’s behalf. Transcriptic provides deep transparency into how users’ experiments were run by executing experiments exactly as specified and also providing retrospective diagnostic data on individual instrument performance during the experiment.
  • Flexible robotics: Being a robotic cloud lab, the Transcriptic system can dynamically provision robotic resources to process samples for users. For example, the system might start the week at a scale of one plate and end the week on hundreds of plates. Users only pay for the resources they use, reaping the reproducibility and throughput benefits of robotics without any of the overhead.
  • Easy multiplexing: The Transcriptic web application makes it easy as checking a box to detect an additional analyte in your sample. When it’s that easy, you can perform multiplexed quantiation of more analytes, starting to generate a more accurate picture of the phenotypic state of your sample.

Featured Service: Mesocale Discovery (MSD) Assay

The MSD assay, validated in many bioanalytical methods per U.S. FDA and EMA guidances, is offered as a service by Transcriptic. The Mesoscale Discovery Sector S 600 instrument is fully integrated with the Transcriptic robotic cloud lab.

The MSD S 600 instrument performs multiplexed detection of up to 10 analytes per well, ensuring the highest data-to-sample quantity efficiency, in immunoassays. Multiple assay panels are available from the V-Plex line, all conducted with complete automated precision by robots in the cloud. Custom panel assays are also available through the MSD U-Plex system.

Why requesters choose Transcriptic

Transcriptic, in collaboration with multiple biopharma companies and non-academic laboratories, has delivered many peer-reviewed publications and conference presentations.

Transcriptic presented one interesting study at SynBioBeta 2016. In collaboration with EpiBiome, Transcriptic’s automated platform provided a robust, reproducible and high-throughput method for on-demand microbiome characterization. This workflow captured sample prep through NGS and sequencing analysis in 7-10 days, allowing for fast, iterative cycles of microbiome screening.

Visit the Transcriptic storefront today to request some quotes!

 

In vivo Phenotypic Screening: Melior Discovery

August 19, 2017 | Posted by Team in Provider Spotlight |

By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

Melior Logo

Phenotypic Screening Pioneer Launches Novel Analgesia Panel

In this Provider Innovation Profile, we’re proud to feature Melior Discovery, a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.

Melior’s platform evaluates compounds through up to 40 different animal models representing 14 broad therapeutic areas, potentially uncovering therapeutic efficacy that might be undetected using traditional assessments.

Recently, Melior made the news with its novel opioidTRACE® Analgesic Profiling Platform. Given the need to develop low-abuse analgesics to address the opioid crisis, Melior has configured an in vivo platform aimed at specifically profiling opioid therapeutics and related analgesics.

The opioidTRACE® platform addresses the multiple features characteristic of opioids, including rodent models that evaluate acute analgesia, chronic analgesia, respiratory depression, GI mobility, and abuse liability. In addition to opioid testing, Melior has a wide array of animal models of analgesia ranging models of acute pain to chronic neuropathy models. 

[click to view larger view of opioidTRACE® animal models]Opioid Trace In Vivo Models

Backed by Expertise in In Vivo Screening

Melior’s new panel is just the latest demonstration of the team’s unique know-how in applying “production-mode” methods for in vivo screening across multiple therapeutic areas. Its proprietary theraTRACE® platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models.

Fibrosis is another disease area for which Melior’s panels have exemplified the utility of in vivo  phenotypic screening. Melior has validated models of liver and lung fibrosis; download the validation data for these models from the Resources section of Melior’s Science Exchange storefront.

Why Requesters are Choosing Melior for In vivo Studies

Melior’s capability directly translates to efficiencies combined with high levels of quality for their clients. Positive ratings and testimonials illustrate the benefits that attract repeat business for Melior:

  • High reproducibility and predictive power of in vivo methodologies, models, and assays assuring high quality of data
  • Lower overall costs resulting from the availability of highly cost effective preclinical services from Melior
  • Rapid responses to requests for service and quick turnaround times for preclinical studies
  • Ability to rapidly customize, design, and modify models in response to requests for specialized in vivo services or changes in protocols or unexpected results at any stage of the study

Dr. Sridharan Rajamani, Senior Research Scientist at Gilead Sciences, said that his team chose Melior Discovery because they were responsive and cost effective.  “We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail,” said Dr. Rajamani. “Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.”  

Interested in working with Melior Discovery? Request a quote to start the discussion.

Trinity Bioactives – Measuring Bioactivity in Everything

February 7, 2017 | Posted by Team in Provider Spotlight |

Trinity Bioactives

We’re pretty sure we can measure the bioactivity of almost anything.

‘Bioactive’ is one of those tricky terms… it can mean many things to many people.

Trinity Bioactive’s definition of it is a compound that does something to living tissue.

Trinity’s expertise is to prove that products such as skin cream, honey-based products, green-lipped mussel powders, oils, and other mostly natural products, ‘do’ something. They use other scientists’ internationally published, peer-reviewed methods to verify that product X has Y effect, which they show as evidence of bioactivity.

Trinity solves the problem of many health product companies and developers of being able to demonstrate that their products work.

To this end, Trinity reckons that it can measure the biological presence and activity of almost anything, if it exists.

Dr Paul Davis

Dr Paul Davis – Research Director and CEO – Trinity Bioactives

Research Director and CEO Paul Davis is tempted to say that there’s no product or extract whose biological activity Trinity can’t measure. But, being the experienced biomedical researcher that he is, he prefers to err on the side of caution.

The Wellington-based laboratory, with satellite offices in Melbourne and Salt Lake City, uses assays or models as a proxy to establish that an extract, mixture, compound or product has biologically active and available properties.

The company’s team is consists mostly of PhD holders, who uses almost 200 assay models to measure a diverse range of biological potencies and efficiencies. Many are cell cultures — stomach cells, tumors, or cell models that measure diabetic or skin responses.

“All of our methodologies are peer-reviewed, and written up and published in reputable international scientific and medical journals,” says Paul. “When we put together our study protocols, we cite the papers the methods are based on.”

The studies consist of mostly natural products including the safety, toxicology, and efficacies of honey, bee propolis, dairy products, green-lipped mussels, traditional medicines, emu oil and other oils, and a number of other raw materials.

Manufacturers of nutraceuticals, functional foods, skin care compounds, over-the-counter internet products, supermarkets, and health food stores are among the global clients for whom Trinity carries out its specialized tests.

These clients include companies:

  • developing new processing methods to improve their products
  • looking for useful functionality from their biological waste streams
  • investigating new activities for existing bioactives and products
  • investigating the possible synergistic effect of combining two or more compounds

“Everything we do is customized to the clients’ requirements,” says Paul. “This is based on a Study Plan; an agreement and approval of what and how we are going to measure a biological presence and response. After the conclusion of the study, a confidential report is supplied back to the client.”

“That’s why our conversations with clients beforehand are so important. We’re aware of the latest regulations out of Europe or the USA, we’re up with the latest modeling research, we appreciate a client wants authentic and verifiable data to provide them with an evidence-led, marketing story.”

Trinity Bioactives Lab

Davis says that the experience, methodologies and consultancy practices developed over the company’s 22-year history are major factors in providing cost-effective proof of bioactivity.

The other advantage of operating in a tightly connected, highly-educated, well-regulated market such as New Zealand is that Trinity Bioactives is able to link into the expertise of other researchers and science providers. These include the universities (including the medical schools), the crown research institutes, other R&D companies and institutions and clinical trials groups. “We have a real concentration of facilities and expertise quite close to us,” says Paul.

“We know what we and others can do, and can tap into that. It means that when someone asks if we can do something, we don’t need to say no, as if it is not in our portfolio, we know someone who can help. We just need a day or two to work on a plan. We almost invariably get back with a way we’d provide scientific evidence and proof of what they wish to validate.”

“From a bioactivity point of view, there’s not much that we or our networks can’t scientifically measure and validate,” says Paul.

“We have expertise, connectivity, and can answer important questions for clients about their products… We realize that our clients are seeking data to assist the marketing of their products and we are happy to assist.”


Would you like to work with Trinity Bioactives on your next project? Trinity Bioactives and thousands of other high-quality service providers look forward to doing business with you on the Science Exchange platform. Request a free quote from any of these service providers today!

AsureQuality

November 21, 2016 | Posted by Team in Provider Spotlight |

Science Exchange has top quality service providers located in all parts of the world. Today we’re profiling one of our newest service providers AsureQuality, a New Zealand based provider of food safety and biosecurity services to the food and primary production sectors worldwide.

Science Exchange correspondent Peter Kerr recently paid a visit to their Lower Hutt laboratory where he caught up with Chief Science Officer (CSO) Dr. Harry van Enckevort.

Global mindset drives Kiwi ‘stamp of approval’ enterprise

AsureQuality

Dr. Harry van Enckevort AsureQuality CSO

How does an organisation from the bottom of the world, excel internationally in verifying and stamping its approval on food quality and safety?

The first answer is because New Zealand exports over 90% of the food it produces, and other countries demand assurances of quality and safety against their market access standards.

The second is through 120 years of experience backed by expertise, professionalism and integrity which sees AsureQuality as its home country’s premier food assurances provider. These attributes also see it with significant operations in Australia, Singapore, China and the Middle East.

AsureQuality’s 1700 people have inherited and continue to develop world-leading inspection, auditing, certification, testing, training, advisory and authentication services.

As a recognised Conformity Assessment Body (CAB) it has a mandate that integrates inspection and certification with testing.

Dr. van Enckevort says food is the State Owned Enterprise’s main focus – giving consumers confidence in what they eat while also protecting the brands of countries and companies.

As well as New Zealand clients, customers include very well known non-NZ multinationals, with some of these brands also in the very sensitive infant formula space.

“AsureQuality also has a key role in New Zealand’s food safety regulatory framework and to do that we have to walk the line between customers and regulators. To achieve it we can’t have conflicts of interest. In practice it means across all AsureQuality services, we have to maintain our independence. We can only do that because we carefully cultivate our expertise, professionalism and integrity.”

Dr. van Enckevort says the organisation is based on a deeply skilled people resource underpinned by its science and technical capabilities.

“We also have a worldwide overview – helping take exports out of New Zealand and bringing global perspectives back home,” he says. “That customer focus is a two-way flow; they lead us and we lead them. If we didn’t there is no way we’d have our global expertise in food quality and safety.”

He says the company instills continual improvement through looking at ourselves and customer feedback and surveys.

“We’re constantly looking at what we need to do to stay relevant and ahead of the game and competition,” Dr van Enckevort says. “We’re always looking to find a better way, challenging our people how we can do things better, faster and smarter while still maintaining the quality of our output. Because there’s always changes in customers and industry as well as customer needs, we have feedback loops and responses.”

A particular point of focus is to add value for a customer beyond mere compliance, not simply ticking a box as part of an audit or certification.

When we give customer feedback in an audit, they might ask what the options are to mitigate the issues, “We say, here are some options – we don’t tell them what to do – they need to make their own call,” he says.

For AsureQuality to still be thriving in five years time, “to still have relevance, we will have to be commercially successful.”

“Our market offering will have to continue to be relevant, and we’ll need to maintain our comparative advantage against our competitors. If we do that we’d like to think we’ll have a larger global presence than we presently do. To achieve that we’ll need to continue to have the right people in the right place with the right expertise and service.”

“So far we’ve met the demands of customers and stakeholders all across the world. By maintaining our core focus on science and technology that is how we will continue to provide the services they want, how we will continue to grow.”

AsureQuality Lab


Would you like to work with AsureQuality on your next project? AsureQuality and thousands of other high quality service providers look forward to doing business with you on the Science Exchange platform. Request a free quote from any of these service providers today!

Science Exchange Supplier Spotlight: University of Wisconsin Cardiovascular Physiology Core Facility

January 15, 2016 | Posted by Team in Provider Spotlight |

The Cardiovascular Physiology Core Facility, with over 35 years of research experience, provides researchers with a resource for creating and studying animal models of disease.
While the central focus of the facility is cardiovascular research, the techniques employed are often useful to investigators in other fields. Currently, the facility is conducting studies into diabetes, bone growth, drug toxicology, and gene therapy in liver and skeletal muscle, as well as cardiovascular disease. One of the most popular services provided by the facility is evaluation of the cardiovascular phenotype of transgenic mice.

The facilities include:

Complete animal catheterization laboratory and fluoroscopy suite
Complete animal catheterization laboratory and fluoroscopy suite

Microsurgery Stations
Microsurgery Stations

• Fully-equipped small and large animal operating theaters
• State-of the art echocardiography for large and small animal models
• ECG and blood pressure monitoring via telemetry
• Exercise training and testing
• Physiologic recording equipment
• Sonomicrometry

You can learn more about this lab’s offerings on their storefront.

UCSC Paleogenomics Lab joins quest for moa genome

August 11, 2015 | Posted by Team in Provider Spotlight |

UCSC Logo

Science Exchange is excited to welcome the UCSC Paleogenomics Lab to our platform!

The Paleogenomics Lab is a joint venture between renowned scientists Beth Shapiro, and Richard (Ed) Green. Their research focuses on a wide range of evolutionary and ecological questions, mostly involving the application of genomics techniques to better understand how species and populations evolve through time.

The first Science Exchange project directed to the UCSC Paleogenomics Lab comes from citizen/wannabe scientist and Science Exchange software engineer David Iorns. After a successful Experiment.com crowdfunding campaign David is collaborating with Beth and her team to help perform preliminary sample preparation and analysis. Assuming the samples contain high enough levels of endogenous DNA the prepared libraries will then be sent to collaborator Dr. Guojie Zhang at The Beijing Genomics Institute where the libraries will undergo more rigorous sequencing.

Compiling the genome of an extinct species is an immense challenge. We touched on many of the complexities involved in our original announcement. However the experts participating in the project are world leaders in their field and we are confident significant progress can be made leading to exciting new discoveries about the genetic makeup of this iconic species.

Would you like to collaborate with the UCSC Paleogenomics Lab or any of our other world class laboratories? Learn more about how Science Exchange can accelerate your research.

Lab Profile: Ries Robinson from Medici Technologies

December 4, 2014 | Posted by Tess Mayall in Provider Spotlight |

medici primary color rgbRecently I spoke with Ries Robinson from our lab Medici Technologies. Everything about Medici Technologies is captivating, from the story behind their unique name to their interesting approach to data analysis. Check out more on their specialized approach below!

Q: What is Medici Technologies’ specialty? 

Ries: We analyze data for groups or companies that have data that is so complex that it exceeds their resources. We are a consulting firm that provides expertise in data analysis.

Q: Why did you choose Medici as your name?

Ries: The Medici Effect is the idea that significant breakthroughs in innovation and technology often occur when you cross-pollinate fields. It stems from the Renaissance. For example, a Renaissance family would make the plumber work with the weaver, or someone with a different skill set, and that’s part of what initiated the Renaissance movement.

A lot of what we do is pull different ideas or algorithms from different places. Historically, we’ve worked on complex data analysis of optical signals for measuring chemicals or analytes in the body, but some of our greatest breakthroughs have been by taking algorithms from non-traditional sectors. For example, we can utilize song recognition and gesture recognition tools to classify tissue types. Utilizing methods developed in other applications has been extremely beneficial. Read the rest of this entry »

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com